Research report

Influenza Vaccines Market in Top 5 European Countries to 2022 - Market Size, Development and Forecasts

Format : Pdf

Publish Date: 15th December 2016

Pages: 175

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.

United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.

Five Major European Markets (5MM) covered in the report are as follows:

United Kingdom
France
Italy
Spain
Germany

Major and Promising Vaccines covered in the report are as follows:

Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax

Key Companies Covered in the Report are as follows:

Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate
 
 
Research Methodology


DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by our in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.


Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.


Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.

All the information gathered was then analysed and synthesized by our in–house team of analysts.
1. Executive Summary

2. Influenza Vaccine Market in Top 5 European Countries – Market Overview
2.1 Influenza Vaccine Market
2.2 Number of Persons Vaccinated with Influenza Vaccine
2.3 Influenza Vaccine Market Share
2.4 Persons Being Vaccinated with Influenza Vaccine Share

3. Influenza Vaccine Market Drivers and Barriers
3.1 Market Drivers
3.2 Market Barriers

4. Influenza Vaccine Market in Top 5 European Countries – Geographical Landscape
 
4.1 Germany
4.1.1 Influenza Vaccine Market
4.1.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.1.2.1 Number of 60+ Years of Age Persons Vaccinated
4.1.2.2 Number of Pregnant Women Vaccinated
4.1.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.1.2.4 Number of Healthcare Workers Vaccinated
 
4.2 France
4.2.1 Influenza Vaccine Market
4.2.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.2.2.1 Number of 65+ Years of Age Persons Vaccinated
4.2.2.2 Number of Pregnant Women Vaccinated
4.2.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.2.2.4 Number of Healthcare Workers Vaccinated
 
4.3 Italy
4.3.1 Influenza Vaccine Market
4.3.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.3.2.1 Number of 65+ Years of Age Persons Vaccinated
4.3.2.2 Number of Pregnant Women Vaccinated
4.3.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.3.2.4 Number of Healthcare Workers Vaccinated
 
4.4 United Kingdom
4.4.1 Influenza Vaccine Market
4.4.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.4.2.1 Number of Children Vaccinated
4.4.2.2 Number of 65+ Years of Age Persons Vaccinated
4.4.2.3 Number of Pregnant Women Vaccinated
4.4.2.4 Number of Chronic Medical Condition Persons Vaccinated
4.4.2.5 Number of Healthcare Workers Vaccinated
 
4.5 Spain
4.5.1 Influenza Vaccine Market
4.5.2 Total – Number of Persons Vaccinated with Influenza Vaccine
4.5.2.1 Number of 65+ Years of Age Persons Vaccinated
4.5.2.2 Number of Pregnant Women Vaccinated
4.5.2.3 Number of Chronic Medical Condition Persons Vaccinated
4.5.2.4 Number of Healthcare Workers Vaccinated

5. European Union Influenza Vaccine Market – Regulatory Landscape

6. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations
6.1 Merger & Acquisitions
6.2 Collaboration Deal
6.3 Licensing, Exclusive & Distribution Agreement Deal
6.3.1 Licensing Agreement
6.3.2 Exclusive Agreement
6.3.3 Distribution Agreement

7. Influenza Vaccine – Pipeline Assessment
7.1 Promising Vaccine in Clinical Development
7.2 Promising Vaccine in Early–Stage Development

8. Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013

9. Key Companies Analysis
 
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
9.1.2.1 Fluzone High–Dose Vaccine
9.1.2.2 Fluzone Quadrivalent Vaccine
9.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
9.1.2.4 Vaxigrip Vaccine
9.1.3 Influenza Vaccine Sales Analysis
 
9.2 GlaxoSmithKline (GSK) 
9.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
9.2.1.1 Fluarix Quadrivalent
9.2.1.2 Flulaval Quadrivalent
9.2.2 Influenza Vaccine Sales Analysis & Forecast
 
9.3 AstraZeneca
9.3.1 Business Overview
9.3.2 AstraZeneca – Influenza Vaccine Outlook
9.3.2.1 Fluenz Tetra/FluMist Quadrivalent
9.3.3 Influenza Vaccine Sales Analysis
 
9.4 Protein Sciences Corporation
9.4.1 Business Overview
9.4.2 Protein Sciences Corporation – Influenza Vaccine  Outlook
9.4.2.1 Flublok
 
9.5 Seqirus (CSL Limited) 
9.5.1 Business Overview
9.5.2 Seqirus – Influenza Vaccine Outlook
9.5.2.1 Flucelvax Quadrivalent
9.5.2.2 Afluria Quadrivalent
9.5.2.3 Agrippal
9.5.2.4 Fluad
9.5.2.5 Fluvirin
9.5.2.6 Fluvax
List of Tables

Table 2 1:Top 5 Countries – Influenza Vaccine Market Share (Percent),2010 – 2015
Table 2 2: Top 5 Countries – Forecast for Influenza Vaccine Market Share (Percent),2016 – 2022
Table 2 3: Top Seven Countries – Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2010 – 2015
Table 2 4: Top Seven Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2016 – 2022
 
Table 5 1: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
 
Table 6 1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015
Table 6 2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016
Table 6 3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016
Table 6 4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016
Table 6 5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016

List of Figures

Figure 2–1: Top 5 Countries – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 2–2: Top 5 Countries – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 2–3: Top 5 Countries – Number of Persons Vaccinated with Influenza Vaccine(Million),2010 – 2015
Figure 2–4: Top 5 Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine(Million),2016 – 2022
 
Figure 4–9: Germany – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–10: Germany – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–11: Germany – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–12: Germany – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–13: Germany – Number of 60+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–14: Germany – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–15: Germany – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–16: Germany – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–17: Germany – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–18: Germany – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–19: Germany – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–20: Germany – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–21: France – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–22: France – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–23: France – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–24: France – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–25: France – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–26: France – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–27: France – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–28: France – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–29: France – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–30: France – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–31: France – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–32: France – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–33: Italy – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–34: Italy – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–35: Italy – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–36: Italy – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–37: Italy – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–38: Italy – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–39: Italy – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–40: Italy – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–41: Italy – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–42: Italy – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–43: Italy – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–44: Italy – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–45: United Kingdom – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–46: United Kingdom – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–47: United Kingdom – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–48: United Kingdom – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–49: United Kingdom – Vaccination Coverage Rate (%)
Figure 4–50: United Kingdom – Number of Children Vaccinated(Thousand),2013 – 2015
Figure 4–51: United Kingdom – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022
Figure 4–52: United Kingdom – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–53: United Kingdom – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–54: United Kingdom – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–55: United Kingdom – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–56: United Kingdom – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–57: United Kingdom – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–58: United Kingdom – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–59: United Kingdom – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
Figure 4–60: Spain – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 4–61: Spain – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 4–62: Spain – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 4–63: Spain – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 4–64: Spain – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015
Figure 4–65: Spain – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022
Figure 4–66: Spain – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015
Figure 4–67: Spain – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022
Figure 4–68: Spain – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015
Figure 4–69: Spain – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022
Figure 4–70: Spain – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015
Figure 4–71: Spain – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022
 
Figure 10–1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10–4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10–5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015

 

 

Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

 

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022